Impact of Eslicarbazepine Acetate on Lipid Metabolism and Cardiovascular Risk Factors
Status:
Unknown status
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
Knowing the impact that the use of ESL as adjunctive treatment of partial epilepsy has on
cardiovascular risk factors measured by biochemical and ultrasound parameters compared with
enzyme-inducing AEDs.
Details
Lead Sponsor:
Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud